Background: Trastuzumab is widely used as the treatment of choice for HER2-positive metastatic breast cancer (MBC).
introduction
Breast cancer represents the main cause of cancer morbidity and mortality in women in most countries all over the world [1] .
Metastatic breast cancer (MBC) remains an incurable disease, but in the last decade the development of new cytotoxic drugs and combinations and the introduction of novel targeted agents have permitted to lengthen patient's survival and improve quality of life.
The clinical introduction of trastuzumab, a humanized monoclonal antibody directed against the HER2/neu protein, has drastically altered the lives of many women with HER-2-overexpressing tumors. This anticancer agent plays an important role in breast cancer treatment.
Overexpression of HER-2 and amplification of the HER-2 gene occur in 25%-30% of cases of MBC [2] and are usually associated with a particularly aggressive clinical course and consequently with a poor prognosis and shortened overall survival (OS).
Preclinical models have shown a significant antitumor activity of trastuzumab as a single agent [3] and additive or even synergistic effects in combination with chemotherapy drugs commonly used in the treatment of breast cancer, especially taxanes, vinorelbine and platinum agents [4] .
On the basis of these encouraging observations, multiple clinical trials were designed in order to investigate safety and clinical activity of trastuzumab in MBC, first as monotherapy and subsequently in combination. The response rates achieved as monotherapy were of 20%-25% as first-line therapy [5] and 10%-15% in patients [6, 7] pretreated with chemotherapy for metastatic disease.
Two pivotal phase III trial compared first-line chemotherapy alone with the combination of chemotherapy with trastuzumab in patients with HER/2-positive MBC [8, 9] . The addition of trastuzumab significantly improved all clinical endpoints [time to progression (TTP), RR, duration of response and survival). In these trials, there was an unexpected high frequency of cardiotoxicity in patients treated with trastuzumab and chemotherapy. A retrospective analysis showed that trastuzumab-associated cardiac events mainly occurred with concomitant use of anthracyclines (mainly doxorubicin) [10] .
Consequently, this combination is not currently indicated for clinical use. Several trials have investigated the cardiac safety and efficacy of anthracyclines less cardiotoxic than doxorubicin, such as epirubicin or liposomal formulations of doxorubicin combined with trastuzumab [11, 12] .
Both pivotal trials demonstrated a favorable safety profile for trastuzumab plus taxanes [8, 9] .
This safe and effective combination is recommended as first-line chemotherapy for patients with HER-2-positive MBC.
In order to improve treatment efficacy and for the increasing use of taxanes in the adjuvant setting, new combinations of trastuzumab and chemotherapy drugs, such as vinorelbine, gemcitabine and capecitabine, have been investigated with encouraging results.
One of the most active non-taxane regimen is the combination of trastuzumab with vinorelbine, with RR of 68%-78% as first-line chemotherapy and a good profile of tolerability, also for the absence of alopecia [13] .
Some associations of trastuzumab with chemotherapy combinations have shown interesting data of safety and efficacy. The addition of platinum salts to taxanes and trastuzumab has significantly enhanced the efficacy of this combination doublet [14, 15, 16] .
The potential benefit in a responding patient with MBC to continue trastuzumab with a new chemotherapy drug or in monotherapy is a topic of great interest.
Unfortunately, most of the metastatic patients develop disease progression during the treatment.
In these patients, to stop or continue trastuzumab is controversy [17] .
In the clinical practice, there is a consensus to continue trastuzumab beyond progression supported by preclinical observations and clinical data, but there are no mature data from randomized trials [18] .
Data collected from clinical trials show a good safety profile of trastuzumab combinations and manageable toxic effects that encourage its use in our clinical practice, but an attentive observation is necessary to investigate long-term tolerability, above all in heavily pretreated patients.
We report in this paper our long-term clinical experience on safety and efficacy of trastuzumab as monotherapy or in combination in MBC patients.
patients and methods
We have conducted a retrospective analysis and collected information on 70 women with histological confirmed HER2-positive MBC, who received trastuzumab-based therapy between May 2001 and June 2006. Standard trastuzumab infusion was administrated until disease progression or serious adverse events.
Median age was 57 years and range 31-81 years. Most patients had good performance status at entry (Eastern Cooperative Oncology Group 0 or 1).
Twenty-six patients had positive estrogen and progesterone receptors. Median number of metastatic sites was 2 and range 1-6. Thirty patients had only visceral metastases, 21 in bone or the soft tissue and the remaining 19 patients had metastases in more risk groups.
Most of the women (66%) had received prior chemotherapy in adjuvant or neo-adjuvant setting, with 17 patients receiving anthracycline-based regimens, 2 taxane-containing therapies and 13 both anthracycline-and taxane-based regimens. Adjuvant endocrine therapy was administered in 27 patients.
Ten patients had metastatic disease at the time of primary diagnosis. Twenty-five patients had received a median number of two previous lines of chemotherapy for metastatic disease (range 1-5). Palliative endocrine therapy was administered in 11 patients.
The characteristics of patients are summarized in Table 1 .
statistical analysis
Disease responses were recorded according to the Response Evaluation Criteria in Solid Tumors guidelines [19] . Toxicity was assessed according to the National Cancer Institute Common Toxicity Criteria system [20] and was recorded for the worst episode occurred. Baseline echocardiography data were recorded and the development of left ventricular ejection function (LVEF) during treatment was reported.
(TTP) was defined as the interval from the first day of application of a new therapy line until tumor progression.
OS was calculated from the day of the first administration of trastuzumab-based therapy to the date of death. Patients alive were censored at the date of the last follow-up contact.
We did not perform statistical comparison of the clinical outcomes in different patient settings for the limited number of patients and the descriptive aim of our retrospective analysis particularly focused on long-term tolerability of trastuzumab-based therapy.
results
Trastuzumab was used first time as monotherapy in 12 patients and in combination in 58 patients.
The associations were with vinorelbine (n = 28), docetaxel (n = 17) and paclitaxel (n = 13). Six patients (8%) had a complete response (CR) and 23 (33%) a partial response (PR); 33 (47%) patients showed stable disease (SD) and 8 (12%) had a progressive disease (PD).
Twenty-six patients received a second trastuzumabcontaining therapy, 14 as monotherapy and 12 in combination (four patients with vinorelbine, three with taxanes, two with pegylated liposomal doxorubicin and three with gemcitabine).
Responses for second-line treatment were: 6 (23%) patients had PR, 16 (62%) SD and 4 (15%) PD. Further lines of trastuzumab-based regimen were administered in nine patients with an overall response rate of 22%. A patient treated in third line with the association of pegylated liposomal doxorubicin obtained an interesting CR, after a SD in first line and a PR in the second.
Among patients treated in third or fourth line, no PD was recorded and seven patients obtained a good control of the disease. The tumor responses in the different lines are shown in Table 2 .
(TTP) was 8 months (range 1-44) in the first-line setting, 9 months (range 3-23) in the second line and also 9 months (range 4-19) beyond second line.
The median OS was 19.2 months with a range of 3-62 months.
Median cumulative dose of trastuzumab administered was 5286 mg (range 464-17 940).
Trastuzumab-based therapy was well tolerated also in combination. Cardiotoxicity was manageable and we did not observed signs or symptoms of congestive heart failure or treatment-related deaths. Median LVEF at baseline was 62% and 59% at the end of trastuzumab (recorded for 43 patients). Only a patient discontinued trastuzumab in combination due to grade 2 asymptomatic decrease in LVEF to 40% (baseline 60%). Six patients experienced a reversible asymptomatic decrease in LVEF between 10% and 15% reversible with a short treatment arrest. Two patients developed reversible tachycardia. A transient increase in transaminases was observed in two patients.
Only a patient discontinued treatment due to grade 3 symptomatic increase in bilirubin.
Fever was recorded in four patients, two after the first infusion. Four patient lamented fatigue and a transient rash developed in a patient. The different observed side-effects related to trastuzumab administration are summarized in Table 3 .
Typical toxic effects of the different chemotherapy agents used in the associations were not increased by the concomitant use of trastuzumab.
After a median time of 12 months of trastuzumab therapy (range 4-22), 11 patients (16%) developed brain metastates (BM).
discussion
The clinical introduction of trastuzumab for MBC overexpressing the HER2 protein has changed the clinical outcome of these patients. Trastuzumab can be combined with Annals of Oncology symposium article a wide range of chemotherapy drugs, adding little the toxicity profile of chemotherapy. Discontinuation after disease progression is still standard of care, although different trials report a benefit from the treatment beyond disease progression, changing chemotherapy regimen [21, 22, 23] . The potential benefit in responding patients with MBC to continue trastuzumab with a new chemotherapy drug in monotherapy is a topic of great interest.
We have reported our long-term clinical experience on safety and efficacy profile of trastuzumab. Although with a limited number of patients and in a retrospective report we have no observed significant difference in (TTP) between the different lines of treatment, that should be related to the potential benefit from continued combination treatment, supported also by the clinical benefit obtained. Moreover, we have reported a CR in third line in a patient, who had obtained a SD in first line and a PR in the second. This clinical outcome is unclear, but certainly is related to the complex interactions between HER2 pathway and neoplastic cells.
Controversial is also the higher incidence of BM during trastuzumab treatment [24, 25] that should reflect the improved peripheral tumor control and patient survival and the relative lack of activity of trastuzumab on central nervous system. The incidence of BM in our patients (16%) is in the range commonly reported for breast cancer patients [25] .
Prolonged administration of trastuzumab seems to be a safe approach, with manageable toxic effects. The available data indicate that often cardiotoxicity of trastuzumab therapy may reflect an exacerbation of anthracycline-induced cardiotoxicity in previous treatments [10] , usually not clinical relevant. The only grade 2 cardiotoxicity reported in our report was observed in a patient previously treated in metastatic setting with firstline anthracycline-based chemotherapy.
Twenty-five of our patients were heavily pretreated for metastatic disease (13 patients have also received adjuvant chemotherapy), but have shown a good compliance to the treatment, confirming the good safety profile of trastuzumab.
In summary, the introduction of trastuzumab in our clinical practice has certainly revolutioned the treatment of breast cancer with the development of new active therapeutic options.
Even with the large therapeutic benefits of trastuzumab, avoiding toxic effects remains an important goal and physicians must be vigilant in managing toxic effects and evaluating potential benefits and risk. Further research is warranted to resolve some important controversies on its optimal use. references
